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Objective: To investigate the effects of raloxifene on the hemostatic system in postmenopausal women.
Design: A prospective longitudinal study.
Setting: Outpatient clinic of the Faculty of Medicine of Ribeirão Preto, Brazil.
Patient(s): Sixteen postmenopausal women aged 56.8  5.9 years (mean  SD).
Intervention(s): Raloxifene hydrochloride (60 mg once daily) was administered orally for a period of 6 months.
Main Outcome Measure(s): Plasma activities of coagulation factors (II, V, VII, VIII, IX, X, XI, XII, and
fibrinogen), prothrombin-derived fragment 12, and activated protein C (APC) sensitivity ratio were measured
at baseline and after 1, 3, and 6 months of treatment.
Result(s): Factor VIII activity increased by 17.1% and 26.9% at 3 and 6 months of treatment, respectively,
compared with baseline. Factor XI and FXII activities significantly increased by 10.9% and 43.1%, respectively,
after 6 months compared with baseline. A significant reduction of APC sensitivity ratio also was observed after
6 months of treatment.
Conclusion(s): A procoagulant state characterized by increased factor VIII, XI, and XII plasma levels and by
reduced APC sensitivity was observed after raloxifene therapy in post-menopausal women. (Fertil Steril 2005;
84:1680–4. ©2005 by American Society for Reproductive Medicine.)
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ualoxifene is a selective estrogen receptor modulator and
xerts tissue-selective effects similar to those of estrogen (E)
n bone and serum lipids, without any apparent stimulatory
ffect on mammary and uterine tissues (1–5). The effect of
aloxifene on the cardiovascular system in postmenopausal
omen has been studied, and the favorable results have been
xplained mainly by its effects on metabolic changes in
ipoproteins, homocysteine, and improved endothelium-de-
endent vasomotricity, preventing arteriosclerosis and acting
s a vasodilating agent (6–9).
Despite these benefits, raloxifene therapy increases the
isk of venous thromboembolism (VTE) by approximately
hreefold, a similar effect to that observed with hormone
herapy (HT) (4). Although a large body of data supports a
rocoagulant state related to E administration, there are few
ublished data on the effect of raloxifene on hemostatic
arameters in postmenopausal women. In an article pub-
ished elsewhere (10), we reported that raloxifene therapy is
ssociated with a significant reduction in plasma antithrom-
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Copyright ©2005 American Society for Reproductive Medicine,in activity, suggesting that this effect may contribute to a
rocoagulant state and partly explain the increased risk of
TE in raloxifene users. Here, we report the results of a
ongitudinal study assessing the effects of raloxifene on
ther hemostatic parameters in healthy postmenopausal
omen.
ATERIALS AND METHODS
tudy Subjects
ixteen postmenopausal women were enrolled in a prospec-
ive longitudinal study. General characteristics of the sub-
ects were as follows (values given as mean SD): age, 56.8
5.9 years; duration of menopause, 9.3  5.5 years; and
ody mass index, 25.8 3.7 kg/m2. Postmenopausal status was
efined as cessation of menses for 1 year, with estradiol (E2)
oncentrations of20 pg/mL and follicle-stimulating hormone
FSH) concentrations of 30 mIU/mL.
Women were ineligible if they had a history of thrombo-
mbolic disorders or of hepatic, renal, endocrinological,
astrointestinal, or cardiovascular disease. Other exclusion
riteria were as follows: substantial postmenopausal symp-
oms; abnormal uterine bleeding; a history of uterine, breast,
r ovarian cancer; or clinically relevant abnormalities in
aboratory tests of hematological, renal, and hepatic func-
ion. None of the participants was a smoker or an illicit drug
ser or was taking any medication that might interfere with
aboratory evaluation of the hemostatic system. Subjects
0015-0282/05/$30.00
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Fould not have taken conjugated E or another hormone
eplacement regimen within the previous 3 months.
All participants were given information about the trial,
nd written informed consent was obtained before enroll-
ent. The protocol was approved by the institutional review
oard.
tudy Design
articipants received oral raloxifene hydrochloride (60 mg
nce per day; Eli Lilly and Company, Indianapolis, IN)
uring a period of 6 months for prevention and treatment of
steoporosis. Hemostatic parameters were measured in all
sers at baseline and after 1, 3, and 6 months of treatment.
ther clinical and laboratory parameters considered during
he treatment period were as follows: weight, body mass
ndex, waist–hip ratio, systolic and diastolic blood pressures,
eart rate, blood cell count, and laboratory parameters of
epatic and renal function.
Fasting venous blood samples were collected between 8
M and 10 AM. Before blood collection, the participants
ested in the sitting position for at least 10 minutes. Blood
amples were collected atraumatically from the antecubital
ein with a 21G butterfly infusion set and were placed in
lastic tubes containing an anticoagulant solution (9 mL
hole blood to 1 mL of 3.2% sodium citrate). The blood
amples were immediately transported to the hemostasis
aboratory, platelet-poor plasma was obtained by centrifuga-
ion at 10°C for 20 minutes at 1,500g, and plasma samples
ere stored at 80°C until analysis.
Complete hematological counts and global clotting tests,
ncluding prothrombin time, thrombin time, and activated
artial thromboplastin time, were performed in all samples.
ecommendations of approved guidelines of the National
ommittee for Clinical Laboratory Standards for collection,
ransport, and processing of blood specimens for coagulation
esting were followed strictly (11).
aboratory Assays
o estimate possible effects on the hemostatic system,
lasma activities of coagulation factors (II, V, VII, VIII, IX,
, XI, XII, and fibrinogen), prothrombin-derived fragment
2 (F12), and the normalized activated protein C (APC)
ensitivity ratio (nAPCsr) were measured at baseline and
fter 1, 3, and 6 months of treatment.
Factor assays were performed on an MLA Electra 1600
nalyzer (Automatic Coagulation Analyzer; Medical Labo-
atory Automation, Inc., Pleasantville, NY) by using factor-
eficient substrates (Helena Laboratories, Inc, Beaumont,
X), and nAPCsr was measured by using a commercial
ctivated partial thromboplastin time-based assay, the
EClot aPC Sensitivity (TECO Medical Instruments, Neu-ahrn, Germany). The quantitative determination of F12 t
ertility and Sterilityas performed by using a sensitive enzyme immunoassay
it, the Enzygnost F12 (Dade Behring, Inc, Deerfield, IL).
tatistical Analysis
he normality of distribution of variables was tested by
sing the Kolmogorov–Smirnov test. The results were ex-
ressed as mean  SD at different periods, and the adjusted
ean changes from baseline with two-sided 95% confidence
ntervals were estimated and statistically tested by Student’s
aired t test. Statistical significance was defined as P.05.
ESULTS
linical and Laboratory Follow-Up
e observed no clinically evident thromboembolic events
uring the study. Significant increases in mean body weight
0.65 kg) and body mass index (0.27 kg/m2) were ob-
erved after 6 months of therapy, compared with baseline
P.05). No significant changes were observed in waist-to-
ip ratio, heart rate, or blood pressure during the study. No
ignificant differences were observed either in biochemical
arameters such as fasting glycemia, creatinine, urea, total
ilirubin, -glutamyl-transferase, alanine aminotransferase,
spartate aminotransferase, and C-reactive protein.
Mean hemoglobin (grams per deciliter) and hematocrit
percentage) levels, for pretreatment assessment, were 13.4
1.0 and 39.4  2.94, respectively, without significant
odifications during the study period. Similarly, no changes
ere verified in leukocyte and platelet counts, with baseline
alues of 5.5  1.62 (103 per microliter) and 225.6  34.17
103 per microliter), respectively.
emostatic Factors
o significant alterations were observed in coagulation
creening tests (activated partial thromboplastin time, pro-
hrombin time, and thrombin time; data not shown). How-
ver, when evaluating plasma activities of coagulation fac-
ors, we observed significant modifications for factors VIII,
I, and XII after raloxifene administration.
A gradual increase in plasma factor VIII level was ob-
erved, and this effect was significant at 3 and 6 months
ompared with baseline (17.1 and 26.9%, respectively;
.05). Also, an increase in plasma factor XI level after 6
onths, compared with baseline (10.9%; P.05), was
bserved. A marked increase in activity was observed in
elation to factor XII after 1, 3, and 6 months of raloxifene
herapy, compared with baseline (34.6%, 49.5%, and
43.1%, respectively; P.05). The mean values of plasma
brinogen levels, F12 concentrations, and activities of
ther coagulation factors were unchanged among study pe-
iods (Table 1).
We also observed that nAPCsr reduced significantly from
.1  0.4 (baseline) to 2.8  0.4 (P.05) after 6 months of
herapy with raloxifene.
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VISCUSSION
aloxifene increases the risk of VTE similarly to what has
een observed with tamoxifen and E use in postmenopausal
omen (4, 12–14). In the Multiple Outcomes of Raloxifene
valuation (MORE) trial, the risk of venous thromboembolic
isease (deep venous thrombosis or pulmonary embolism)
as found to be 3.1 times higher (95% confidence interval,
.5 to 6.2) in women assigned to the raloxifene group than to
he placebo group. These findings led those investigators to
ecommend that women with a history of VTE should not
ake raloxifene and that women currently taking this medi-
ation should discontinue it before major surgery or during
eriods of immobilization (4).
The reasons that a woman on raloxifene therapy is at a
TABLE 1
Comparison of parameters across study periods
Parameter Baseline
Fibrinogen
Mean  SD 289.9 43.8 271
Change from baseline 18.1 (
Factor II
Mean SD 100.6 12.9 99
Change from baseline 0.8 (
Factor V
Mean  SD 129.6 18.6 127
Change from baseline 1.8 (
Factor VII
Mean  SD 118.1 21.1 110
Change from baseline 8.1 (
Factor VIII
Mean  SD 90.1 32.4 99
Change from baseline 9.2 (
Factor IX
Mean  SD 77.3 19.6 80
Change from baseline 2.9 (
Factor X
Mean  SD 106.9 13.2 107
Change from baseline 0.4 (
Factor XI
Mean SD 96.4 24.0 104
Change from baseline 8.1 (
Factor XII
Mean  SD 147.8 53.7 182
Change from baseline 34.6 (
F12
Mean  SD 0.8 0.2 0
Change from baseline 0.0 (
Note: Values are expressed as mean SD at different perio
intervals).
a P.05 compared with baseline, Student’s t test.
Dantas Azevedo. Raloxifene and hemastatic system. Fertil Steril 2005.igher risk of VTE are not well understood. Hemostatic a
1682 Dantas Azevedo et al. Raloxifene and hemostatic systemffects of raloxifene on hemostasis have been explored only
artially, and the information available comes from clinical
rials attempting to assess isolated points of the hemostatic
ystem. Walsh et al. (9) performed a multicentric study
omparing raloxifene, HRT, and placebo and assessing fi-
rinogen, plasminogen activator inhibitor-1, F12, and fi-
rinopeptide A levels. In that study, the investigators ob-
erved a significant reduction in fibrinogen levels of 10% to
2% among raloxifene users, an effect not observed in the
RT group. No significant alterations associated to ralox-
fene were detected in F12, fibrinopeptide A, and plasmin-
gen activator inhibitor-1 levels. In another study involving
ore extensive assessment of the hemostatic system, De
alk-de Roo et al. (15) also observed a fibrinogen reduction
o 3 mo 6 mo
52.1 281.1 51.6 309.1 48.4
.7, 9.6) 8.8 (44.7, 27.1) 19.1 (8.3, 46.6)
13.5 101.2 15.1 100.2 13.9
, 4.3) 0.6 (3.5, 4.8) 0.4 (5.0, 4.1)
15.3 133.9 19.0 132.3 16.5
, 5.7) 4.2 (1.3, 9.8) 2.7 (1.9, 7.3)
18.3a 115.6  21.8 116.4 25.6
.8, 2.4) 2.6 (9.2, 4.1) 1.7 (6.0, 2.5)
32.5 107.2 33.9a 117.1 36.6a
, 20.2) 17.1 (3.1, 31.0) 26.9 (8.3, 45.6)
17.6 78.1 13.7 78.5 17.2
, 10.0) 0.8 (8.4, 10.0) 1.2 (5.5, 7.8)
15.0 108.8 18.8 109.4 19.1
, 4.4) 1.9 (2.5, 6.4) 2.5 (2.0, 7.0)
37.5 98.9 29.3 107.4 24.9a
.1, 29.2) 2.4 (9.2, 14.1) 10.9 (0.5, 21.4)
63.0a 197.3 55.6a 190.9 60.3a
, 58.8) 49.5 (25.5, 73.5) 43.1 (13.5, 72.6)
0.2 0.8  0.2 0.8 0.3
, 0.1) 0.0 (0.1, 0.1) 0.0 (0.1, 0.1)
d adjusted mean changes from baseline (95% confidence.
1 m
.9
45
.9
5.8
.9
9.2
.1
13
.4
1.7
.2
4.2
.3
3.6
.5
13
.4
10.5
.8
0.1
ds anssociated with raloxifene use but without significant alter-
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Ftions in other coagulation parameters assessed. In relation
o fibrinolysis assessment, no significant modifications were
etected in any of the parameters considered, in groups
hich received raloxifene. Conversely, estrogen (E) replace-
ent caused plasminogen activator inhibitor-1 reduction (a
eneficial effect) but a transitory increase in F12, suggest-
ng a greater thrombin generation and activation of coagu-
ation in this treatment group.
The present study was designed specifically to determine
he effects of raloxifene on the hemostatic system by using
xtensive assessment methodology and rigorous sample se-
ection criteria to include healthy postmenopausal women,
ithout additional risk factors for arterial or venous throm-
osis. In our study, we observed statistically significant
ncreases in the procoagulant activity levels of factors VIII,
I, and XII after raloxifene use. The increase in factor VIII
ctivity particularly is important in relation to VTE risk,
ecause a significant association has been reported between
igh factor VIII levels and a greater predisposition to throm-
oembolic disease. The associated relative risk with high
actor VIII levels is around 4.8, and it is estimated that for
ach 10-IU/dL (or 10% of coagulant activity) increment, the
isk for a single episode of VTE increases by 10%, and that
or recurrent disease, by 24% (16–18).
By analyzing the interaction of venous thrombosis risk
actors in oral hormonal contraceptive users, Bloemenkamp
t al. (19) reported a 3.8- to 4-fold risk increase associated
ith the isolated presence of high factor VIII levels or prior
ontraceptive use. However, after analyzing the effect of the
ssociation of these two risk factors on VTE occurrence,
hose investigators verified a 10-fold risk increase. This
vidence suggests that the 26.9% increase in factor VIII
rocoagulant activity observed in our study may represent a
lausible pathophysiological mechanism by which ralox-
fene therapy contributes to VTE occurrence in postmeno-
ausal women.
In relation to the other coagulation factors, we observed
hat raloxifene treatment caused significant increases in fac-
or XI and XII activity levels. Coagulation factor XI con-
ributes to thrombin generation and is involved in both fibrin
ormation and protection against fibrinolysis (20, 21), and
he increase in its coagulant activity level also has been
ssociated with increased VTE risk (22). Thus, it is possible
hat the increase in factor XI plasma levels associated with
aloxifene use that is described in this study also may con-
ribute to VTE risk in users of this medication.
We verified a 34.6% increase in factor XII activity at 1
onth and an even greater increment at 3 and 6 months
49.5% and 43.1%, respectively). However, the contribu-
ion of this significant and progressive increase of coag-
lation factor XII level for VTE risk after raloxifene use
s not clear because there is no scientific evidence indi-
ating a significant association between factor XII level w
ertility and Sterilityncrease and VTE occurrence. Thus, the clinical relevance
r the pathophysiological consequence of this finding is
ot possible to establish in light of current scientific
nowledge.
Resistance to the anticoagulant action of APC is a highly
revalent risk factor for venous thrombosis among individ-
als of Caucasian origin (23). In most cases, APC resistance
s associated with a single missense mutation in the gene for
oagulation factor V, designated factor V Leiden. However,
poor APC response also may result from several acquired
onditions, some of which clearly are involved in the patho-
enesis of venous thrombosis, such as inflammatory dis-
ases, pregnancy, hormonal contraceptive use, and elevated
evels of fibrinogen and factor VIII (23, 24). Data indicate
hat acquired reduction in sensitivity to APC is associated
ith a 2.5- to 4-fold VTE risk increase and that the combi-
ation of the risk factors of HRT use and APC resistance is
ssociated with an approximately 13-fold increase in VTE
isk in women (25, 26).
In our study, we reported that raloxifene use is associated
ith a reduction in sensitivity to APC, suggesting that this
echanism also could be involved in the increased throm-
otic risk related to raloxifene therapy in postmenopausal
omen. These results are not in agreement with those of a
ecent report that raloxifene had no significant effect on
APCsr compared with placebo in both women and men
27), and the reasons for these contrasting findings remain to
e explained.
Some investigators have shown that the presence of ele-
ated factor VIII levels is associated with lowered nAPCsr,
ven in the absence of factor V Leiden (28–30). The patho-
hysiological mechanism of this association can be under-
tood by considering the physiological role of protein C,
ecause its anticoagulant activity is through the cleavage and
nactivation of factors Va and VIIIa, in such a way that the
ccurrence of a significant increase in factor VIII levels may
ead to a state of APC resistance.
The results of this prospective study show for the first time
hat raloxifene use is associated with significant increases in
lasma factors VIII, XI, and XII levels and with an acquired
PC resistance state, all of which, except factor XII, are
ell-established risk factors for VTE. Additionally, in an
rticle published elsewhere, we found that raloxifene admin-
stration significantly decreased plasma antithrombin activity
t 3 months (5.1%) and 6 months (6.5%) of treatment,
uggesting that this effect also may contribute to a proco-
gulant state and partly explain the increased risk of VTE in
aloxifene users. Compared with baseline, raloxifene did not
ignificantly affect protein C activity or protein S level (10).
aken together, the results suggest that these effects may
ead to a procoagulant state, conceivably contributing to the
ncreased VTE risk that is observed in postmenopausal
omen treated with raloxifene.
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